SCHEMBL2245451

SCHEMBL2245451

CNc1[c]c2ccccc2cc1

nearest known ligand 0.38

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 1/20 0.38
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9637938 0.78 IDO1 (0.32)
SCHEMBL4723785 0.78 MEN1 (0.33)
SCHEMBL3174946 0.75 ALDH1A1 (0.44) TSHR
SCHEMBL5961725 0.75 KEAP1 (0.43)
SCHEMBL4723126 0.75 APP (0.34)
SCHEMBL6662392 0.75 HSD17B10 (0.42)
SCHEMBL27466799 0.74
SCHEMBL8877645 0.74 ALDH1A1 (0.39) TSHR
SCHEMBL4724480 0.72 TLR8 (0.41) TSHR
SCHEMBL7571610 0.71 APP (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030109517-A1 Azacycloalkanone serine protease inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. 2003-06-12 US claimed
EP-2524686-B1 PIGMENTATION-PREVENTING OR -AMELIORATING AGENT POLA CHEM IND INC (JP) 2017-06-21 EP disclosed
EP-2514402-B1 PREVENTING OR AMELIORATING AGENT FOR PIGMENTATION POLA CHEM IND INC (JP) 2016-08-31 EP disclosed
US-9414998-B2 Preventing or ameliorating agent for pigmentation POLA CHEMICAL INDUSTRIES INC. (JP) 2016-08-16 US disclosed
US-9066914-B2 Prophylactic or ameliorating agent for pigmentation POLA CHEMICAL INDUSTRIES INC. (JP) 2015-06-30 US disclosed
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
US-20140322150-A1 PREVENTING OR AMELIORATING AGENT FOR PIGMENTATION POLA CHEMICAL INDUSTRIES INC. (JP) 2014-10-30 US disclosed
US-20140163222-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors FORMA THERAPEUTICS, INC. (US) 2014-06-12 US disclosed
US-20140163006-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors FORMA THERAPEUTICS, INC. (US) 2014-06-12 US disclosed
US-20140163003-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors FORMA THERAPEUTICS, INC. (US) 2014-06-12 US disclosed
US-5053304-A Photoconductor element for making multiple copies and process for using same EASTMAN KODAK COMPANY (US) 1991-10-01 US disclosed
US-4452943-A ADDING NITRILE-CONTAINING MATERIAL TO NON-POLAR THERMOPLASTIC POLYMER GOLDMAN CONRAD 1984-06-05 US disclosed
US-4197120-A ELECTRICALLY PHOTOSENSITIVE PARTICLES CONTAINING COLORANT HAVING ABSORPTION MAXIMUM GREATER THAN 410 NANOMETERS EASTMAN KODAK COMPANY (US) 1980-04-08 US disclosed
US-RE30235-E FOR ELECTROPHORETIC MIGRATION IMAGING PROCESSES EASTMAN KODAK COMPANY (US) 1980-03-18 US disclosed
US-4175961-A DISPERSION OF A POLYMER HAVING ALKYLIDENE DIARYLENE GROUPS, A PYRYLIUM-TYPE DYE SALT, AND A BIS(N,N-DISUBSTITUTED ANILINE DERIVATIVE AS A SENSITIZER EASTMAN KODAK COMPANY (US) 1979-11-27 US disclosed
US-4127412-A BIS(AMINOARYL)ALKANES EASTMAN KODAK COMPANY (US) 1978-11-28 US disclosed
US-4111693-A PYRYLIUM TYPE DYE SALT EASTMAN KODAK COMPANY (US) 1978-09-05 US disclosed
US-4092162-A Nitrogen containing polymers aelements EASTMAN KODAK COMPANY (US) 1978-05-30 US disclosed
US-4025341-A CONDENSATION POLYMER OF A TERTIARY AROMATIC AMINE, A SENSITIZER, AND A CARBONYL COMPOUND EASTMAN KODAK COMPANY (US) 1977-05-24 US disclosed
US-4012376-A Photosensitive colorant materials EASTMAN KODAK COMPANY (US) 1977-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140163006-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors DCK, PDXK, CDK2 NCF1 2876/4885TSHR 2483/4885
US-20140163003-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors DCK, PDXK, CDK2 NCF1 2876/4885TSHR 2483/4885
US-20140163222-A1 Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors DCK, PDXK, CDK2 NCF1 2876/4885TSHR 2483/4885
US-20140322150-A1 PREVENTING OR AMELIORATING AGENT FOR PIGMENTATION TYR, MC1R, MITF NCF1 671/4885TSHR 1691/4885
US-20030109517-A1 Azacycloalkanone serine protease inhibitors CTRL, SERPINE1, SERPINB1 NCF1 1190/4885TSHR 3005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.